Status:
COMPLETED
Observational Study to Evaluate the Safety of Levemir® in Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (ins...
Eligibility Criteria
Inclusion
- Age according to approved label in each country and physician discretion
- Type 1 or 2 diabetes
- Recently started treatment with insulin detemir at the discretion of the investigator. Before initiation of insulin detemir they should not have been treated with insulin
- Selection at the discretion of the physician
Exclusion
- Current treatment with Levemir® (insulin detemir)
- Previously enrolled in the study
- Hypersensitivity to Levemir® (insulin detemir)
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
51170 Patients enrolled
Trial Details
Trial ID
NCT00659295
Start Date
June 1 2004
End Date
March 1 2010
Last Update
March 10 2017
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Brussels, Belgium, 1070
2
Novo Nordisk Investigational Site
Prague, Czechia, 16000
3
Novo Nordisk Investigational Site
Copenhagen S, Denmark, 2300
4
Novo Nordisk Investigational Site
Espoo, Finland, FI-02600